Vortioxetine: 6 agencies, 2014–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused vortioxetine: all 7 decisive outcomes across 5 agencies were positive or positive with restrictions.
Assessment has run over 10.5 years, from 26 Nov 2014 at TLV (Sweden) to 27 May 2025 at TLV (Sweden).
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and AWMSG (Wales) among them — hold no record for vortioxetine at all.
Against its own class, vortioxetine is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class N06A average 71%.
TLV (Sweden) was first to assess vortioxetine, on 26 Nov 2014; CHUIKYO (Japan) did not open a file until 13 Nov 2019 — a wide spread of 5 years between the earliest and latest system to look at it.
Restriction is doing real work here: 5 of 7 decisive outcomes narrowed vortioxetine to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland) among others.
2 of the 6 agencies here assessed vortioxetine more than once, TLV (Sweden) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for vortioxetine.
The full ledger for vortioxetine reads 5 restricted, 2 recommended and 1 appraised.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 27 May 2025 | Brintellix ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| HAS (France) | 15 Dec 2021 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| CHUIKYO (Japan) | 13 Nov 2019 | トリンテリックス: cost-effectiveness evaluation (new product, high price or high sales) | evaluation completed, price adjustment decided | source |
| AOTMIT (Poland) | 5 Apr 2019 | Brintellix reimbursement recommendation | recommended conditionally | source |
| SMC (Scotland) | 11 Jul 2016 | Treatment of major depressive episodes in adults. | accepted (restricted) | source |
3 further decisions for vortioxetine, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- escitalopram — divergent outcome (restricted vs other) on a shared indication
- agomelatine — divergent outcome (restricted vs recommended) on a shared indication
- esketamine — same ATC class N06A — Psychoanaleptics
- duloxetine — same ATC class N06A — Psychoanaleptics
- venlafaxine — same ATC class N06A — Psychoanaleptics
- paroxetine — same ATC class N06A — Psychoanaleptics
Coverage: 8 decisions for vortioxetine from 6 agencies, 2014 to 2025. Data to 7 Sep 2026. ATC class N06A — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.